是时候对癌症疗法进行价值评估了

肿瘤治疗的价值评估方式并不总是与科学同步. 癌症负担正在增加, and 现在是时候继续发展癌症治疗价值评估了 to help improve patient access. This consulting report was initiated, 并由im体育资助. im体育委托BCG编写了这份报告 which outlines seven principles and three recommendations to evolve value assessment of cancer therapies.

人们对癌症疗法的评价并不总是与科学发展同步. 全球癌症发病率预计将从19.300万到30万.2040年200万，¹ 现在是时候继续发展癌症治疗价值评估了. 一份新报告, 是与BCG和一个全球癌症专家组合作开发的, outlines seven principles for 纳税人 and 监管机构 to realign value assessment strategies to keep pace with science. This consulting report was initiated, 并由im体育资助. im体育委托BCG编写了这份报告.

对癌症疗法不断发展的价值评估可能支持患者及时获得治疗
The journey to advance cancer care has seen scientific advances in innovation over the last few decades. 同时, scientific advances in oncology have led to more targeted treatments for patients with the aim to improve clinical outcomes and quality of life.^2,3,4

病人的访问
让癌症患者从早期发现和治疗的进步中受益, 他们需要获得创新疗法. 在许多国家, 在药物获得监管机构批准后, 对其价值进行评估，以便为付款人的报销和获取决策提供信息. ⁵ The clinical effectiveness and safety evidence required by 监管机构 to inform a marketing authorisation decision can differ from the evidence 纳税人 use to inform reimbursement and access decisions as part of their value assessment. ⁵ 这可能导致延迟或不一致的患者访问.⁶

政策需要包括癌症治疗的全方位价值衡量
确保患者和医疗保健系统能够获得并受益于癌症创新, the global cancer community needs to continue to evolve how oncology treatments are valued to allow reimbursement to keep pace with science. 病人的访问 to innovative medicines in the early stages of disease not only increases chance of improved outcomes, 癌症早期诊断每年节省的治疗费用是巨大的.⁷

To help improve access to innovation in cancer therapies we collaborated with Boston Consulting Group (BCG) and a global expert group representing patient advocates, 纳税人, 健康经济学家, 监管机构, 来自专业肿瘤学会和医生的代表. Thanks to their collective expertise and insight, we are honoured to share a new report, The evolving value assessment of cancer therapies: Seven principles from the cancer community.

The report outlines seven principles: four outline cancer therapy value assessment that could be used for assessing the clinical value of treatments for earlier-stage cancers, and three represent important value components that could be integrated into healthcare system assessments and processes. The report also sets out three recommendations and nine actions for the cancer community to take together toward the goal of improving access to new medicines for early-stage cancer.  阅读报告 The evolving value assessment of cancer therapies: Seven principles from the cancer community 在这里 并与你的网络分享.

更多的 needs be done to ensure the scientific advances in innovation over the last few years continue to advance cancer care and reach patients. Patients and physicians should not lose out on innovative treatments that could improve clinical outcomes and quality of life due to rigid value assessments. It is t在这里fore time to evolve Health Technology Assessments (HTA) and payer value assessments to accelerate access to oncology medicines.

Giuseppe Curigliano博士
米兰大学肿瘤医学教授

作为一个癌症社区, im体育首页必须利用这一点来合作推进价值评估, 因此，患者可以及时获得创新的肿瘤药物. Scientific advances in cancer innovation means t在这里 is an opportunity to improve patient outcomes, 然而, patients cannot benefit if barriers in value assessment continue to limit access to oncology medicines.

癌症负担正在增加, with global cancer incidence estimated to increase from 19.300万到30万.2040年200万. 与2020年相比，2040年诊断出癌症的人数增加了近1100万.¹ 作为一个癌症社区, 在这份新报告中, we are calling on 纳税人 and 监管机构 to continue to evolve how oncology medicines are valued to improve access to scientific advances. 反过来, early intervention with effective and targeted treatments will both improve patient outcomes and help health systems combat the rising burden of cancer.

贝丝汉密尔顿
全球肿瘤市场准入和定价副总裁

本文中提到的咨询报告是发起的, 并由im体育资助. im体育委托BCG编写了这份报告.